Chronic atrophic gastritis
Conditions
Interventions
Treatment group:Eolian Granules
Control Group:None
Sponsors
Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 85 Years
Inclusion criteria
Inclusion criteria: (1) Age between 18 and 85 years, regardless of gender; (2) Pathological diagnosis by endoscopy confirmed early gastric cancer (dysplasia/low- or high-grade intraepithelial neoplasia), and received endoscopic submucosal dissection (ESD) within the past 3 months, with postoperative adherence to PPI therapy for 4-8 weeks; (3) If infected with Helicobacter pylori (Hp), Hp has been eradicated; (4) Patients diagnosed with spleen deficiency with blood stasis and heat according to traditional Chinese medicine (TCM) differentiation; (5) Pregnant women of childbearing age must undergo a pregnancy test to exclude pregnancy.
Exclusion criteria
Exclusion criteria: (1) Patients who are planned to undergo additional surgical procedures after gastric ESD surgery; (2) Patients with severe digestive system diseases or a history of abdominal surgery; (3) Patients with malignant tumors or severe primary diseases of the heart, brain, lungs, hematopoietic system, etc., poorly controlled diabetes, severe hepatic or renal insufficiency, including those with liver function impairment (alanine aminotransferase > 1.5 times the upper limit of normal) or renal impairment (serum creatinine > 1.5 times the upper limit of normal); (4) Pregnant or breastfeeding women; (5) Patients who have been taking NSAID medications long-term; (6) Patients with disabilities as defined by law (blindness, deafness, muteness, intellectual disabilities, mental disorders, physical disabilities); (7) Patients with a history of alcohol abuse or addiction to other substances; (8) Patients with a history of allergies or hypersensitivity to multiple drugs (two or more) or known components of this medication; (9) Patients who have participated in other drug clinical trials within the past 4 weeks, or have used folic acid, Muluodan, or similar preparations within the past 2 weeks; (10) Patients deemed likely to be lost to follow-up or otherwise unsuitable for inclusion, as judged by the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Histological grading of spasmolytic polypeptide metaplasia; | — |
Secondary
| Measure | Time frame |
|---|---|
| Endoscopic Mucosa Evaluation;Histopathological evaluation; | — |
Countries
China
Contacts
Public ContactLiu Chang
Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine
Outcome results
None listed